Company: AGIO
Filing Date: 2025-02-13
Form Type: 8-K
Source: 0001193125-25-025524
Chunk: 0

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-02-13
Form: 8-K
Item: Item 5.02
Chunk 0
---
Item 5.02      Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.  

On February 10, 2025, David P. Schenkein, M. D., notified Agios Pharmaceuticals, Inc. (the “ Company”) of his decision to resign from the Board of Directors of the Company (the “ Board”), effective February 28, 2025. Upon his resignation from the Board, Dr. Schenkein will also cease serving as a member of the Science and Technology Committee of the Board. Dr. Schenkein will continue to serve as a strategic advisor to the Company’s leadership team, concentrating on advancing the Company’s clinical development programs.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                               AGIOS PHARMACEUTICALS, INC.                               
  Date: February 13, 2025      By:                              /s/ Brian Goff           
                                                                Brian Goff               
                                                                Chief Executive Officer